Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial

Single-center randomized crossover open-label trial in adults with type 2 diabetes mellitus. 33 completed; 20 female and 13 male; median age 64 years; mean duration of diabetes ~11 years; well-controlled diabetes (HbA1c 6.5-9.0%) on stable medications.

Calcium-magnesium IP6 capsules, 380 mg IP6 per capsule; three capsules daily with main meals; duration per intervention: 12 weeks.

IP6 diet reduced circulating AGEs by ~25% and HbA1c by ~3.8% after 3 months in adults with T2DM; non-IP6 diet showed no significant changes. Effects were maintained during IP6 exposure and diminished after follow-up. IP6 intake increased urinary IP6 excretion; IP6 was well tolerated with no serious adverse events; one severe hypoglycemic event occurred in non-IP6 group. Authors conclude IP6 inhibits protein glycation and may help prevent diabetes-related complications; they call for larger, multicenter blinded trials to confirm findings.

Small, single-center open-label crossover study with 33 participants; potential carryover effects; relatively short duration; limited generalizability; adherence and dietary confounds; lack of blinding may bias outcomes.